They demonstrated that PRAME expression was positive in the majority of both primary and metastatic melanoma (83.2% and 87%, respectively) and negative in the majority of benign melanocytic nevi (86.4%) [19]. This evidence concerns the gene PRAME and metastatic melanoma.